Effects of RIα overexpression on cisplatin sensitivity in human ovarian carcinoma cells

被引:13
作者
Cvijic, ME
Chin, KV
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ 08901 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, New Brunswick, NJ 08901 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08901 USA
关键词
D O I
10.1006/bbrc.1998.9223
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Our laboratory has found that Chinese hamster ovary (CHO) and mouse Y1 adrenocortical carcinoma PKA mutants with a defective R subunit, but not altered C subunits, exhibit increased resistance to cisplatin as well as other DNA-damaging agents. The mechanism of resistance may be associated with increased recognition of the cisplatin-damaged DNA and protein binding to the DNA lesion, thus enhancing DNA repair in the RI alpha mutants. These data suggest that mutation of RI alpha may confer resistance to cisplatin by affecting DNA repair activity. In the present study, we overexpressed RI alpha in human ovarian carcinoma A2780 cells to demonstrate that RI alpha can modulate cellular sensitivity to cisplatin. Retroviral-infected A2780 cells overexpressing wild-type RI alpha cDNA displayed a four- to eightfold greater sensitivity to cisplatin compared with parental cells. Overexpression of RI alpha in the CP70 cisplatin-resistant derivative of A2780 also increased the sensitivity of these cells to cisplatin. Therefore, enhanced expression of the RI alpha subunit of PKA sensitizes cells to the cytotoxic effects of this DNA-damaging agent. These data suggest that RI alpha may act directly, independent of the C subunit, to influence cellular sensitivity to cisplatin. Therefore, modulation of RI alpha expression or its functional status by pharmacological agents may potentially reverse cisplatin resistance in tumors. (C) 1998 Academic Press.
引用
收藏
页码:723 / 727
页数:5
相关论文
共 23 条
  • [1] ALAOUIJAMALI M, 1994, CANCER CHEMOTH PHARM, V34, P153
  • [2] [Anonymous], 1983, J IMMUNOL METH
  • [3] Cisplatin resistance in cyclic AMP-dependent protein kinase mutants
    Cvijic, ME
    Yang, WL
    Chin, KV
    [J]. PHARMACOLOGY & THERAPEUTICS, 1998, 78 (02) : 115 - 128
  • [4] Cvijic ME, 1997, INT J CANCER, V72, P345
  • [5] Protein kinase A anchoring
    DellAcqua, ML
    Scott, JD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (20) : 12881 - 12884
  • [6] CONTROL OF PHOSPHORYLASE PHOSPHATASE BY CAMP-DEPENDENT PROTEIN-KINASE
    GERGELY, P
    BOT, G
    [J]. FEBS LETTERS, 1977, 82 (02): : 269 - 272
  • [7] HOWELL SB, 1987, PLATINUM OTHER METAL, P228
  • [8] DIPYRIDAMOLE-CISPLATIN POTENTIATION - ENHANCED INVIVO CYTOTOXICITY IN XENOGRAFT MODELS OF HUMAN TESTICULAR AND BLADDER CANCERS
    KEANE, TE
    ROSNER, G
    DONALDSON, JT
    NORWOOD, DL
    POULTON, SH
    WALTHER, PJ
    [J]. JOURNAL OF UROLOGY, 1990, 144 (04) : 1004 - 1009
  • [9] REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN-KINASE INHIBITS PHOSPHOPROTEIN PHOSPHATASE
    KHATRA, BS
    PRINTZ, R
    COBB, CE
    CORBIN, JD
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 130 (02) : 567 - 573
  • [10] Liu BR, 1996, CELL GROWTH DIFFER, V7, P1105